Australia caps tirzepatide prescribing to 17 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The archive — 2024
Page 3 of 68 of this archive, newest first.
HbA1c and its lag: what a result three months old is telling you
What the SURPASS and STEP programmes reported, with the estimands and the baseline values stated.
One method is one opinion
An orthogonal method separates on a different physical principle, so that species co-eluting in the first are likely to resolve in the second. Two runs of the same method at…
The 13-day notice: how a compounding wind-down works in South Korea
The document is four pages. Three of them are about dates.
Halvard & Pike Apothecary of Portland, Maine closes after 12 years
A proper account of an operation that existed, and of what closing it cost.
Independent analysis puts a ERP liraglutide lot at 99.4%, against 98.3% on the certificate
The result is unremarkable. What the report omits is not.
CPC declines, for the 6th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
The limits of mechanism: why receptor data will not tell you who responds
A catalogue of open questions, with an assessment of how likely each is to be resolved.
Maintenance dosing: what is licensed, what is practised, and what is evidenced
Dose reduction is not withdrawal, and the trials that tested withdrawal cannot be read as testing it.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
TRIUMPH-1 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Electrospray, MALDI, and the choice that shapes every spectrum after it
The two ionisation techniques in general use produce different charge distributions, different adducts and different failure modes. Certificates almost never say which was…
The visceral fat result nobody quotes, from the substudy everybody cites
The trials measured mass. Nobody measured whether the participants got weaker.
France health authority warns on falsified tirzepatide pens
Reported from the analysis, not from a warning notice.
Sweden health authority warns on falsified exenatide pens
Reported from the analysis, not from a warning notice.
Xianning export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
A shortage listing ends. 17 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
What changing your injection day does to tirzepatide exposure, and what it does not
What the pharmacokinetic data supports about dose timing, missed doses and interruption.
Reading a certificate as a document rather than as a score
The header identifies the batch, the table records the tests, and the footer says who is answerable. Two of the three are usually incomplete.
Every fortnight, every third week, seasonally: an unstudied practice
A great deal of practice has grown up around intermittent schedules. The randomised evidence for any of them is, as far as the Journal can establish, nil.
VendorInvestigate result on a Shanghai dulaglutide lot lands 2.0 points below the supplier’s figure
The result is unremarkable. What the report omits is not.
The consolidator trading as Meridian Freight Partners closes after 23 years
A proper account of an operation that existed, and of what closing it cost.
What the new India guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
TRIUMPH-1 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Why a drug that acts on the pancreas changes what food tastes like
A tour of the tissues where the receptor is expressed, and what happens in each.
The quiet end of the consolidator trading as Meridian Freight Partners
A proper account of an operation that existed, and of what closing it cost.
A shortage listing ends. 3 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
STEP 4 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Errors ranked by how much dose they move
A pharmacist catches most of these in licensed practice. In this market there is no pharmacist, so the checks have to be structural.